The antimicrobial properties of cephalosporin P1, an antibiotic structurally related to fusidic acid, were examined. Cephalosporin P1 exhibited potent activity against methicillin-sensitive Staphylococcus aureus, methicillin-resistant S. aureus and vancomycin-intermediate S. aureus. Mutants of S. aureus resistant to cephalosporin P1 arose with a frequency of 1.6 × 10 -6 for selections at 4 × MIC, a frequency similar to that for fusidic acid. The mutations conferred crossresistance to fusidic acid and mapped in fusA, the gene encoding elongation factor G. Crossresistance between cephalosporin P1 and fusidic acid also occurred for S. aureus fusA mutants selected with fusidic acid, and in fusidic acid-resistant clinical isolates. Plasmid pUB101, which mediates resistance to fusidic acid in S. aureus, also conferred resistance to cephalosporin P1. Escherichia coli was intrinsically resistant to both fusidic acid and cephalosporin P1, but deletion of the AcrAB efflux pump resulted in susceptibility to both antibiotics. Although complete cross-resistance between fusidic acid and cephalosporin P1 was demonstrated, the nature and location of fusA mutations in S. aureus when cephalosporin P1 was the selective agent frequently differed from those selected with fusidic acid. This may reflect differences in the interaction of the two antibiotics with the translational apparatus, which results in the selection of separate mutation classes for each antibiotic. Furthermore, in three of 14 mutants selected with fusidic acid, resistance was attributed to mutations lying outside fusA. In contrast, mutations in 10 mutants selected with cephalosporin P1 were all located in fusA.
Introduction
Resistance to antibiotics is becoming a difficult problem in the management of infections caused by Gram-positive bacteria. 1 The situation is particularly critical for treatment of infections caused by Staphylococcus aureus where methicillin-resistant (MRSA) and vancomycin-intermediate resistant (VISA) strains have emerged, which are also frequently resistant to multiple classes of antibiotics. 2 The recent report of an MRSA isolate resistant to the new oxazolidinone antimicrobial linezolid 3 is a further disturbing trend in the evolution of antimicrobial resistance in staphylococci. There is therefore a need to discover and develop new approaches for combating S. aureus. 4 Several new strategies for controlling staphylococcal infections have been considered in recent years. These include the use of antibiotic combinations, [5] [6] [7] the development of new members of existing antibiotic classes 2, 4, 8 and the discovery of novel agents through genomic approaches. 9 Another approach is the re-evaluation of older, unexploited agents, with a view to developing them for use against organisms resistant to current agents. 10, 11 This concept has already been applied to daptomycin, an antibiotic discovered in the early 1980s, which is now undergoing clinical trials for application as an agent to control infections caused by Gram-positive pathogens, including S. aureus. 12 Recently, at the pre-clinical level, we have assessed the potential of older, unexploited, natural product RNA polymerase inhibitors as anti-staphylococcal agents. 8, 13 Cephalosporin P1 (The nomenclature here is confusing. Cephalosporin P1 is not related to the cephalosporins that 14 Early work demonstrated that cephalosporin P1 has an antibacterial spectrum that predominantly encompasses Gram-positive organisms, with particularly potent activity against S. aureus. 14, 15 However, no recent work on cephalosporin P1 has been conducted. In view of its excellent activity against S. aureus, including in vivo activity, 15 we decided to re-evaluate this antibiotic as a potential anti-staphylococcal agent.
Cephalosporin P1 is structurally related to fusidic acid (Figure 1 ), an antibiotic introduced in 1962 for treatment of staphylococcal infections. 16 In view of the increasing incidence of fusidic acid resistance in clinical isolates of S. aureus, 17, 18 an important issue for the development of cephalosporin P1 is possible cross-resistance with fusidic acid-resistant strains. In clinical isolates, resistance to fusidic acid can arise from mutations in fusA, the gene that encodes elongation factor G (EF-G) and is the target of fusidic acid action. 19, 20 In addition, resistance in natural isolates may also result from acquisition of fusB, a poorly characterized plasmid-mediated resistance mechanism. 20, 21 Although crossresistance between fusidic acid and cephalosporin P1 has been described for a laboratory-derived fusidic acid-resistant mutant, 14 the nature of the mutation or mutations responsible for resistance was not reported. Furthermore, it is unknown whether plasmid-mediated fusidic acid resistance confers cross-resistance to cephalosporin P1.
Results reported in this paper confirm the excellent antistaphylococcal activity of cephalosporin P1 and address in detail the issue of cross-resistance between fusidic acid and cephalosporin P1 in S. aureus. For this purpose, we have used laboratory mutants with defined mutations in fusA, 22 a strain harbouring pUB101, which encodes the fusB plasmidmediated mechanism, 21 and a set of fusidic acid-resistant clinical isolates. 18 In all cases we observed cross-resistance between fusidic acid and cephalosporin P1, and novel mutations in fusA conferring resistance to both antibiotics were identified. In addition, using a mutant deleted for the AcrAB efflux system in Escherichia coli, we demonstrated that cross-resistance between the two antibiotics extends to a Gram-negative efflux pump. Some of the results reported here were presented in a preliminary communication. 22 
Materials and methods

Bacterial strains
S. aureus and E. coli laboratory strains are listed in Table 1 . Clinical bacteria used for comparative susceptibility testing were isolates maintained in a culture collection belonging to 
Determination of susceptibility to antimicrobial agents
MICs were determined by agar dilution on MHA or ISA using an inoculum in MHB or ISB of 10 6 cfu/spot for S. aureus and 10 4 cfu/spot for E. coli. 23 The MIC was defined as the lowest concentration of antibiotic completely inhibiting visible growth after 18-24 h incubation at 37°C.
Determination of mutation frequencies for resistance to antimicrobial agents
This was carried out as described by O'Neill et al. 5 using ISA. Both standard and concentrated cell techniques were used, whereby mutation frequencies as low as 1 in 10 -11 can be detected. Mutant colonies were normally counted after incubation of plates for 24 h at 37°C. However, mutants resistant to ciprofloxacin were slow growing and in this case colonies were quantified after 48 h incubation.
Selection of fusidic acid-and cephalosporin P1-resistant mutants
Fusidic acid-resistant mutants were generated by growing S. aureus 8325-4 in ISB at 37°C with shaking to a culture density at 600 nm of ∼1, and plating 100 µL aliquots onto ISA at either 0.25 or 10 mg/L. For cephalosporin P1, resistant mutants were selected at 0.25 mg/L. After 24 h incubation at 37°C, colonies were picked at random from the selective plates and their susceptibilities (MICs) to fusidic acid and cephalosporin P1 established on ISA.
Plasmid curing
Loss of resistance to fusidic acid (plasmid curing) in clinical isolates of S. aureus following incubation at 43°C was carried out essentially as described by Lacey & Grinsted. 24 However, loss of resistance was monitored by replica plating onto ISA containing fusidic acid at 0.5-16 mg/L to identify colonies that had become more susceptible to fusidic acid.
PCR and DNA sequencing
Oligonucleotide primers for PCR and DNA sequencing were designed using Oligo 5.0 (MBI, Cascade, ID, USA) and purchased from MWG Biotech (Milton Keynes, UK). DNA templates were prepared using the QIAamp DNA mini kit (Qiagen) according to the manufacturer's instructions. Extensor Hi-fidelity Master mix (ABgene, Epsom, UK) was used for all amplifications under standard PCR cycling conditions. 25 Primers for amplification of the entire ∼2.1 kb fusA gene were fusF (5′-CGCGGATCCTATCGTATTTATTC-AGTAAT) and fusR (5′-AAGGATCCCTTGTATTTTAA-CCTAGGCTA) and were based on sequence data from the S. aureus NCTC 8325 genome (http:// www.genome.ou.edu/ staph.html). Successful amplification was confirmed by agarose gel electrophoresis. 25 DNA was eluted from gels by solubilizing the agarose in QG buffer (Qiagen), and purified using the QIAquick PCR Purification Kit (Qiagen).
DNA sequencing of fusA was carried out using the amplification primers and three additional sequencing primers (5′-GCGTCAGGCTACAACTTATGG, 5′-CAATAGTTA-CTTTCATCATTGG and 5′-TTATTGGTCACCGTGCT-AGCAACC) by Lark Technologies Incorporated (Saffron Walden, UK) on an Applied Biosystems 377 DNA sequencer.
Deletion of acrAB in E. coli 1411
Although strain JZM120 (JC7623 ∆acrAB::Tn903kan r ) 26 ( Table 1) was donated to us, its parent (JC7623) was not available. Therefore, to determine the effects of deleting acrAB on antibiotic susceptibility, we constructed an acrAB knock-out in one of our laboratory strains (E. coli 1411; Table 1 ) to provide an isogenic pair. A ∆acrAB 1411 strain was constructed by P1 transduction 27 of ∆acrAB::Tn903kan r from JZM120, resulting in strain SM1411. Deletion of acrAB was confirmed by generation of a PCR amplicon from a primer specific for the Tn903 kanamycin kinase gene (5′-TCCGACCATCAAG-CATTTTA) and one specific for the acrB gene (5′-CAG-CAGCACGAACATACCA), and by increased susceptibility to puromycin, erythromycin, novobiocin and linezolid, as reported previously 28, 29 (Table 6) .
Results
In vitro anti-staphylococcal activity of cephalosporin P1
The in vitro anti-staphylococcal activity of cephalosporin P1 has been reported for only a limited number of strains and the data are not expressed in conventional MIC format. 14, 15 Furthermore, comparative data with other anti-staphylococcal agents are not available. Therefore the activity of cephalosporin P1 against a number of clinical isolates of S. aureus (MSSA, MRSA and VISA) was determined by dilution in MHA and compared with that of cefotaxime, ceftriaxone, cefepime, fusidic acid, linezolid, oxacillin, quinupristin/ dalfopristin and vancomycin (Table 2) . Cephalosporin P1 was slightly less active than fusidic acid against the panel of 67 strains tested. Nevertheless, it displayed excellent antistaphylococcal activity, including those strains resistant to established agents.
Mutation frequency for resistance to cephalosporin P1 and comparison with other agents
Selection of S. aureus mutants resistant to cephalosporin P1 has been reported, 30 but the frequency with which mutants arise has not been determined. Spontaneous mutants of S. aureus 8325-4 resistant to cephalosporin P1 were recovered by direct plating of organisms on to ISA containing the antibiotic at 4 × MIC. Mutants arose with a frequency of 1.6 × 10 -6 ( Table 3) . Frequencies of mutational resistance to a number of other anti-staphylococcal agents, including fusidic acid, were determined under identical conditions (Table 3) . Mutation frequencies were cephalosporin P1 > fusidic acid > rifampicin > norfloxacin > mupirocin > ciprofloxacin. No mutants were recovered (frequencies <10 -11 ) when bacteria were selected on vancomycin or penicillin at 4 × MIC.
Cross-resistance between fusidic acid and cephalosporin P1 in chromosomal mutants selected with fusidic acid
To assist the evaluation of cephalosporin P1, we cross-screened the antibiotic against a collection of fusidic acid-resistant mutants of S. aureus 8325-4, generated in an isogenic background (Table 4 ; Figure 2 ). Mutations in fusA were identified in 11 of 14 mutants selected for study and were located in the three clusters (I-III) reported previously for mutations conferring resistance to fusidic acid in S. aureus and Salmonella 33 who also reported unidentified chromosomal loci that confer fusidic acid resistance in S. aureus. The S. aureus fusidic acid-resistant mutants that we derived all displayed cross-resistance to cephalosporin P1 (Table 4) . In all cases, the level of resistance to cephalosporin P1 was greater than that displayed for fusidic acid.
Cross-resistance between cephalosporin P1 and fusidic acid in chromosomal mutants selected with cephalosporin P1
In addition to determining cross-resistance patterns for mutants initially selected with fusidic acid, we reversed the approach by selecting mutants resistant to cephalosporin P1 followed by examination of cross-resistance to fusidic acid (Table 4) . In all cases, mutants selected on the basis of resist- ance to cephalosporin P1 were also resistant to fusidic acid. The levels of resistance to cephalosporin P1 displayed by these mutants were greater than those for fusidic acid, as noted previously for mutants selected with fusidic acid as the primary agent. To determine whether the changes responsible for resistance in mutants selected with cephalosporin P1 arose in fusA, the complete gene was sequenced in 10 mutants covering the cephalosporin P1 MIC range (2-64 mg/L) observed for these mutants. Mutations were identified in each of the fusA clusters I-III at amino acid residues 118, 404, 406, 436, 452, 478, 656 (three mutants) and 666. With the exception of T 436 -I and G 452 -S, which confer fusidic acid resistance in S. aureus, the mutations did not correspond exactly to those we, or others, observed when fusidic acid was used as the primary selective agent (Table 4 ; Figure 2 ). Thus, the mutations at residues 478, 656 and 666 are novel since they have not previously been associated with resistance to fusidic acid, whilst T 118 -I, which has been reported to confer fusidic acid resistance in S. typhimurium, was detected for the first time in S. aureus. Mutations at amino acid residues 404, 406 and 452 have previously been associated with resistance to fusidic acid in S. aureus, as described above and in Figure 2 . However, the actual substitutions identified following selection with cephalosporin P1 were novel. In contrast to selections with fusidic acid, mutants selected with cephalosporin P1 appeared to contain mutations only in fusA.
Cross-resistance between fusidic acid and cephalosporin P1 mediated by plasmid pUB101
Although the molecular basis of plasmid-mediated resistance to fusidic acid in S. aureus has not been established, it is not related to that conferred by mutant EF-G. 21 It was therefore of interest to determine whether the plasmid-mediated fusidic acid resistance mechanism also conferred cross-resistance to cephalosporin P1. For this purpose, we used plasmid pUB101, which specifies resistance to fusidic acid. 21 Plasmid pUB101 conferred resistance to both fusidic acid and cephalosporin P1 when present in S. aureus strain 649, raising the MICs of these drugs by factors of 128 and 256, respectively (Table 5) .
Cross-resistance between fusidic acid and cephalosporin P1 in clinical isolates of S. aureus
Results described above suggested that clinical isolates of S. aureus resistant to fusidic acid would also exhibit crossresistance to cephalosporin P1. This was explored by screening some of the fusidic acid-resistant S. aureus strains originally isolated from clinical material by Ravenscroft et al. 18 Strains chosen for analysis exhibited a range of resistance levels to fusidic acid (MICs 2-256 mg/L). High-level fusidic acid resistance (16-256 mg/L) appeared to be associated with possession of plasmids, since heat treatment of strains H5, Figure 2 . Amino acid substitutions in the three clusters of EF-G that confer resistance to fusidic acid. In each case, EF-G from S. aureus is indicated on the top line (this study; 19, 33 ) and EF-G from S. typhimurium is indicated on the bottom line. 31 Mutations in S. aureus detected only following selection on cephalosporin P1 (this study) are shown boxed.
H10, H56 and H71, under conditions that promote plasmid curing, 24 resulted in decreased resistance to fusidic acid (Table 5 ). In contrast, with the exception of strain H84 (fusidic acid MIC 8 mg/L), heat treatment of isolates exhibiting lowlevel resistance to fusidic acid (MIC 2-8 mg/L) failed to decrease the resistance levels. Thus, presumptive evidence was obtained for the occurrence of both chromosomal and plasmid-mediated mechanisms of fusidic acid resistance in the clinical isolates. In all cases cross-resistance with cephalosporin P1 was observed (Table 5) . Residual resistance to both fusidic acid and cephalosporin P1 was observed in those strains that had been subjected to plasmid curing ( Table 5) .
The AcrAB efflux pump in E. coli mediates resistance to both fusidic acid and cephalosporin P1
In addition to the mechanisms of fusidic resistance described above, the AcrAB efflux system in E. coli mediates resistance to fusidic acid. 28, 34 To determine whether AcrAB also mediates resistance to cephalosporin P1, we compared its activities against a wild-type E. coli K12 strain (1411) and an isogenic derivative deleted in acrAB (SM1411). Deletion of acrAB resulted in an ∼10-fold increase in susceptibility to cephalosporin P1 (Table 6 ). The activities of fusidic acid, puromycin, novobiocin, erythromycin and linezolid were all enhanced (16-to 64-fold) against strain SM1411 (∆acrAB) ( Table 6) . These antibiotics are all substrates of the AcrAB efflux pump. 28,29,34
Discussion
The possibility of developing older antibiotic classes to combat resistance to existing agents has been suggested by ourselves 10,13 and others. 11 Although cephalosporin P1 possesses potent anti-staphylococcal activity, spontaneous mutants resistant to the drug are selected with high frequency. This suggests that if developed, cephalosporin P1 would probably need to be combined with other agents to suppress emergence of resistance in the clinical setting. 5 Bacterial resistance to one member of an antibiotic structural series does not necessarily mean that cross-resistance will be exhibited to other analogues within the family, e.g. the glycylcyclines, although sharing many structural features with earlier tetracyclines, are not subject to the efflux and ribosomal protection mechanisms that confer resistance to earlier members. 35 However, the structural similarity between fusidic acid and cephalosporin P1 (Figure 1 ) suggests the possibility of cross-resistance between the two antibiotics. This situation has not previously been explored in detail, but data reported here demonstrate that mutations in all three clusters of EF-G that confer resistance to fusidic acid also confer cross-resistance to cephalosporin P1. This situation extends to mutants selected with cephalosporin P1, which all mapped in fusA (encoding EF-G) and displayed crossresistance to fusidic acid. A further mechanism of resistance to fusidic acid in S. aureus involves a plasmid-mediated system 21 that has been designated fusB. 36 Although the molecular basis of fusB-encoded resistance has yet to be determined, early studies clearly differentiate it from EF-G-based mutational resistance. 21 Nevertheless, cross-resistance with cephalosporin P1 was also exhibited at the level of fusB.
Since mutations in fusA and acquisition of fusB are both responsible for resistance to fusidic acid in clinical isolates of S. aureus, 19, 20 we were not surprised to observe that a collection of fusidic acid-resistant clinical strains also exhibited cross-resistance to cephalosporin P1. We have not yet determined the exact status of these clinical isolates with respect to mutations in fusA and carriage of fusB. However, resistance of some strains (H3, H36 and H69) to both antibiotics was unaffected by treatment leading to plasmid loss. This suggests that these strains may only contain fusA mutations. In contrast, derivatives of other clinical isolates (H5, H10, H56, H71 and H84) that were apparently cured of plasmid determinants nevertheless retained residual resistance to both fusidic acid and cephalosporin P1 (Table 5) . These results are therefore consistent with the possibility that the original clinical isolates (H5, H10, H56, H71 and H84) contained both chromosomal fusA mutations and plasmid-located fusB determinants. The collection of clinical isolates studied here is therefore likely to contain the fusidic acid resistance genotypes commonly occurring during therapy with fusidic acid. Consequently, the increasing incidence of fusidic acid resistance in clinical isolates of S. aureus 17, 18 is undoubtedly an issue when considering whether cephalosporin P1 might be developed as an antibiotic candidate.
In addition to mutations in fusA, other uncharacterized chromosomal mutations confer resistance to fusidic acid in staphylococci. 19, 22, 33 Although it is not clear whether such mutants arise in the clinic, these strains were also crossresistant to cephalosporin P1 (Table 4) . Finally, although fusidic acid has no application in the treatment of infections caused by E. coli, 20 we demonstrated a further cross-resistance relationship between fusidic acid and cephalosporin P1 at the level of the AcrAB efflux pump. Furthermore, we noted that even when the AcrAB efflux pump was deleted, the MICs of fusidic acid and cephalosporin P1 for this E. coli mutant were greater than those observed for the antibiotic-sensitive staphylococcal strains 8325-4 and 649. It is known that the lipid bilayer region of the Gram-negative outer membrane is relatively impermeable to lipophilic molecules. 37 Since fusidic acid and cephalosporin P1 are lipophilic molecules, the residual insusceptibility of E. coli SM1411 (∆acrAB) to these antibiotics probably reflects poor uptake across the Gram-negative outer membrane.
Apart from exploring the potential of cephalosporin P1 as an anti-staphylococcal agent, this study has provided further insights into structure-function relationships in fusA. This relates to the nature and location of mutants selected with fusidic acid and cephalosporin P1 (Figure 2) .
Despite the spread of resistance loci across EF-G, some sites appear to be especially important for the development of fusidic acid resistance, particularly the conserved region 38 centred on residues 451-464 (Figure 2 ). This region, and in particular H 457 , is thought to interact directly with fusidic acid. 33 Removal of histidine per se from this site is not sufficient to generate high-level resistance, as the nature of the substitution at residue 457 influences susceptibility to fusidic acid. For example, an H→Y replacement results in a mutant with a fusidic acid MIC of 64 mg/L, whereas an H→N replacement generates a mutant with an MIC of 256 mg/L (Table 4 ). Despite the fact that H 457 is highly conserved, EF-G function is nonetheless retained with any of three different residues in its place (Table 4 ). However, analysis of mutant F32 (Table 4) suggests that the nature of the histidine-replacement residue is not immaterial; this strain carries two nucleotide substitutions (CAC-CTA) in a single codon. It is likely that mutation CAC-CAA (H 457 →Q) took place first, rather than CAC-CTC (H 457 →L); if histidine was first replaced with leucine, a second, silent nucleotide substitution would need to arise subsequently in the same codon. Conceivably, mutation Q 457 , despite conferring a degree of fusidic acid resistance, exhibited unsatisfactory translocase activity, resulting in subsequent selection of the compensatory mutation CAA-CTA (Q 457 →L).
Although we observed cross-resistance between fusidic acid and cephalosporin P1, there appeared to be differences in the nature and location of mutations selected by the two agents in S. aureus (Figure 2 ). The majority of mutations selected with cephalosporin P1 either arose at novel sites within fusA, or involved different substitutions from those arising with fusidic acid selection. Furthermore, all the mutants selected with cephalosporin P1 contained mutations in fusA, in contrast to three of the 14 mutants selected with fusidic acid that did not map to fusA (Table 4) . Examination of the effects of fusidic acid and cephalosporin P1 on translocation and peptide bond formation using cell-free assays suggests that the interaction of the two antibiotics with EF-G may differ. 39 Possibly, the differences in EF-G binding characteristics of cephalosporin P1 favour the selection of different types of mutation in EF-G compared with selection with fusidic acid. However, whether there is a real difference in the spectrum of mutations selected by each agent will require examination of larger numbers of mutants.
